8-K Announcements
6Material company update
Mar 18, 2026·SEC
Material company update
Feb 2, 2026·SEC
Material company update
Jan 12, 2026·SEC
ProKidney Corp.(PROK)Earnings, Financials & Key Ratios
PROK•NASDAQ
$1.88
$299M mkt cap·Price updated May 7, 2026
AboutProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.Show more
- Revenue$893K+1075.0%
- EBITDA-$159M+10.6%
- Net Income-$152M-147.8%
- EPS (Diluted)-0.51+17.7%
- Gross Margin-540.76%-640.8%
- EBITDA Margin-17837.07%+92.4%
- Operating Margin-18477.83%+92.4%
- Net Margin-16977.83%+78.9%
- ROE-43.17%-179.7%
- ROIC-49.41%-14.9%
- Debt/Equity0.01+22.3%
- Interest Coverage-41251.75-102.1%
PROK Key Insights
ProKidney Corp. (PROK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Shares diluted 36.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PROK Price & Volume
ProKidney Corp. (PROK) stock price & volume — 10-year historical chart
Loading chart...
PROK Growth Metrics
ProKidney Corp. (PROK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM1075%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-12.75%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM17.46%
Return on Capital
10 Years-160.97%
5 Years-92.89%
3 Years-41.99%
Last Year-46.5%
PROK Recent Earnings
ProKidney Corp. (PROK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
Mar 18, 2026EPS
$0.14
Est $0.16
+12.5%
Revenue
$223,000
Est $600
+37066.7%
Q4 2025
Nov 10, 2025EPS
$0.12
Est $0.12
+0.0%
Revenue
$217,000
Q3 2025
Aug 12, 2025EPS
$0.13
Est $0.14
+7.1%
Revenue
$221,000
Est $44,250
+399.4%
Q2 2025
May 12, 2025EPS
$0.13
Est $0.16
+18.8%
Revenue
$230,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 18, 2026 | $0.14vs $0.16+12.5% | $223,000vs $600+37066.7% |
| Q4 2025 | Nov 10, 2025 | $0.12vs $0.12+0.0% | $217,000 |
| Q3 2025 | Aug 12, 2025 | $0.13vs $0.14+7.1% | $221,000vs $44,250+399.4% |
| Q2 2025 | May 12, 2025 | $0.13vs $0.16+18.8% | $230,000 |
Based on last 12 quarters of dataView full earnings history →
PROK Peer Comparison
ProKidney Corp. (PROK) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 RGEN | 7.13B | 126.43 | 147.01 | 16.36% | 6.73% | 2.46% | 0.33 | |
 ALLO | 520.77M | 2.27 | -2.61 | -100% | -57.07% | 0.26 | ||
 SANA | 917.92M | 3.50 | -3.02 | -120.02% | 0.38 | |||
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare PROK vs Peers
ProKidney Corp. (PROK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PROK Income Statement
ProKidney Corp. (PROK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 76K | 893K |
| Revenue Growth % | - | - | - | - | - | - | 1075% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 5.72M |
| COGS % of Revenue | - | - | - | - | - | - | 640.76% |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 76K▲ 0% | -4.83M▼ 6453.9% |
| Gross Margin % | - | - | - | - | - | 100% | -540.76% |
| Gross Profit Growth % | - | - | - | - | - | - | -6453.95% |
| Operating Expenses | 79.38M | 27.02M | 55.11M | 153.01M | 151.52M | 183.75M | 165.9M |
| OpEx % of Revenue | - | - | - | - | - | 241778.95% | 18577.83% |
| Selling, General & Admin | 4.16M | 5.98M | 8.86M | 70.94M | 44.81M | 56.08M | 51.78M |
| SG&A % of Revenue | - | - | - | - | - | 73794.74% | 5798.1% |
| Research & Development | 75.22M | 21.04M | 46.26M | 82.07M | 106.71M | 127.67M | 114.12M |
| R&D % of Revenue | - | - | - | - | - | 167984.21% | 12779.73% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -79.38M▲ 0% | -27.02M▲ 66.0% | -55.11M▼ 103.9% | -153.01M▼ 177.6% | -151.52M▲ 1.0% | -183.68M▼ 21.2% | -165.01M▲ 10.2% |
| Operating Margin % | - | - | - | - | - | -241678.95% | -18477.83% |
| Operating Income Growth % | - | 65.96% | -103.93% | -177.64% | 0.97% | -21.22% | 10.16% |
| EBITDA | -78.51M | -26.06M | -53.13M | -149.97M | -147.67M | -178.24M | -159.28M |
| EBITDA Margin % | - | - | - | - | - | -234531.58% | -17837.07% |
| EBITDA Growth % | - | 66.81% | -103.86% | -182.29% | 1.54% | -20.71% | 10.64% |
| D&A (Non-Cash Add-back) | 867K | 964K | 1.98M | 3.04M | 3.85M | 5.43M | 5.72M |
| EBIT | -19.16M | -27.02M | -55.11M | -147.02M | -129.44M | -163.92M | -164.69M |
| Net Interest Income | 126 | 43K | 2K | 5.77M | 22.07M | 19.74M | 13.81M |
| Interest Income | 126 | 43K | 2K | 5.98M | 22.08M | 19.75M | 13.81M |
| Interest Expense | 0 | 0 | 0 | 215K | 12K | 9K | 4K |
| Other Income/Expense | 126K | 43K | 2K | 5.77M | 22.07M | 19.74M | 13.49M |
| Pretax Income | -79.25M▲ 0% | -26.98M▲ 66.0% | -55.11M▼ 104.2% | -147.24M▼ 167.2% | -129.45M▲ 12.1% | -163.93M▼ 26.6% | -151.2M▲ 7.8% |
| Pretax Margin % | - | - | - | - | - | -215701.32% | -16931.47% |
| Income Tax | 361K | -232K | 38K | 896K | 6M | -598K | 414K |
| Effective Tax Rate % | -0.46% | 0.86% | -0.07% | -0.61% | -4.63% | 0.36% | -0.27% |
| Net Income | -79.61M▲ 0% | -26.75M▲ 66.4% | -55.15M▼ 106.2% | -108.03M▼ 95.9% | -35.47M▲ 67.2% | -61.19M▼ 72.5% | -151.61M▼ 147.8% |
| Net Margin % | - | - | - | - | - | -80507.89% | -16977.83% |
| Net Income Growth % | - | 66.4% | -106.16% | -95.9% | 67.17% | -72.51% | -147.79% |
| Net Income (Continuing) | -79.61M | -26.75M | -55.15M | -148.13M | -135.45M | -163.34M | -151.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 1.6B | 1.49B | 1.4B | 1.31B |
| EPS (Diluted) | -1.01▲ 0% | -0.14▲ 86.1% | -1.73▼ 1135.7% | -1.76▼ 1.7% | -0.57▲ 67.6% | -0.62▼ 8.8% | -0.51▲ 17.7% |
| EPS Growth % | - | 86.14% | -1135.71% | -1.73% | 67.61% | -8.77% | 17.74% |
| EPS (Basic) | -1.01 | -0.14 | -1.73 | -1.76 | -0.57 | -0.62 | -0.51 |
| Diluted Shares Outstanding | 78.53M | 186.5M | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
| Basic Shares Outstanding | 78.53M | 186.5M | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
PROK Balance Sheet
ProKidney Corp. (PROK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.42M | 5.58M | 27.27M | 504.72M | 374.15M | 395.88M | 280.68M |
| Cash & Short-Term Investments | 15.23M | 4.58M | 20.56M | 490.25M | 362.95M | 358.29M | 270.02M |
| Cash Only | 15.23M | 4.58M | 20.56M | 490.25M | 60.65M | 99.12M | 108.54M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 302.3M | 259.17M | 161.48M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 1.38M | 2.45M | 1.13M |
| Days Sales Outstanding | - | - | - | - | - | 11.75K | 460.64 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 52K | 25K | 1.38M | 9K | 19.45M | 9.54M |
| Total Non-Current Assets | 4.18M | 11.12M | 13.03M | 13.28M | 46.41M | 45.19M | 54.9M |
| Property, Plant & Equipment | 3.33M | 10.47M | 12.6M | 13.06M | 46.41M | 45.19M | 54.9M |
| Fixed Asset Turnover | - | - | - | - | - | 0.00x | 0.02x |
| Goodwill | 0 | 641.36K | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 857K | 642 | 428K | 213K | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 19.61M▲ 0% | 16.7M▼ 14.8% | 40.3M▲ 141.3% | 518M▲ 1185.4% | 420.55M▼ 18.8% | 441.07M▲ 4.9% | 335.57M▼ 23.9% |
| Asset Turnover | - | - | - | - | - | 0.00x | 0.00x |
| Asset Growth % | - | -14.83% | 141.31% | 1185.41% | -18.81% | 4.88% | -23.92% |
| Total Current Liabilities | 2.71M | 5.5M | 12.31M | 10.87M | 25.04M | 36.22M | 30.74M |
| Accounts Payable | 480K | 781K | 2.83M | 3.04M | 5.1M | 3.63M | 940K |
| Days Payables Outstanding | - | - | - | - | - | - | 59.96 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 355K | 1.71M | 0 | 0 | 7.52M | 11.45M | 29.8M |
| Current Ratio | 5.68x | 1.02x | 2.21x | 46.42x | 14.94x | 10.93x | 9.13x |
| Quick Ratio | 5.68x | 1.02x | 2.21x | 46.42x | 14.94x | 10.93x | 9.13x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.01M | 1.33M | 1.07M | 2.18M | 4.18M | 3.22M | 4.04M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 2.96M |
| Capital Lease Obligations | 1.01M | 1.33M | 1.07M | 1.91M | 3.61M | 2.47M | 2.96M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 278K | 568K | 748K | 1.07M |
| Total Liabilities | 3.72M | 6.84M | 13.38M | 13.06M | 29.22M | 39.44M | 34.78M |
| Total Debt | 1.11M | 1.56M | 1.33M | 2.4M | 4.41M | 3.24M | 2.96M |
| Net Debt | -14.11M | -3.02M | -19.22M | -487.85M | -56.24M | -95.88M | -105.57M |
| Debt / Equity | 0.07x | 0.16x | 0.05x | 0.00x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -711.66x | -12626.83x | -20408.44x | -41251.75x |
| Total Equity | 15.88M▲ 0% | 9.86M▼ 37.9% | 26.92M▲ 172.9% | 504.94M▲ 1775.9% | 391.34M▼ 22.5% | 401.64M▲ 2.6% | 300.79M▼ 25.1% |
| Equity Growth % | - | -37.9% | 172.88% | 1775.91% | -22.5% | 2.63% | -25.11% |
| Book Value per Share | 0.20 | 0.05 | 0.84 | 8.21 | 6.34 | 4.10 | 2.25 |
| Total Shareholders' Equity | 15.88M | 9.86M | 26.92M | -1.1B | -1.1B | -994.95M | 300.79M |
| Common Stock | 95.5M | 116.23M | 188.43M | 24K | 23K | 29K | 30K |
| Retained Earnings | -79.61M | -106.36M | -161.51M | -1.1B | -1.14B | -1.2B | -1.27B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 130K | 130K | 0 |
| Minority Interest | 0 | 0 | 0 | 1.6B | 1.49B | 1.4B | 1.31B |
PROK Cash Flow Statement
ProKidney Corp. (PROK) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -76.81K | -25.18M | -50.3M | -77.09M | -90.07M | -126.35M | -120.12M |
| Operating CF Margin % | - | - | - | - | - | -166251.32% | -13450.95% |
| Operating CF Growth % | - | -32685.2% | -99.75% | -53.26% | -16.84% | -40.28% | 4.93% |
| Net Income | -79.61K | -26.75M | -55.15M | -148.13M | -135.45M | -163.34M | -151.61M |
| Depreciation & Amortization | 867 | 964K | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| Stock-Based Compensation | 498 | 730K | 699K | 74.47M | 30.85M | 29.37M | 25.34M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.56K | 0 | 0 | 0 | -6M | -1.78M | -1.7M |
| Working Capital Changes | -115 | -126K | 2.16M | -6.46M | 16.67M | 3.96M | 1.28M |
| Change in Receivables | 0 | 0 | 0 | 0 | -1.38M | -1.07M | 1.32M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 683K | 5K | 494K | 11.64M | 11.59M | -5.92M |
| Cash from Investing | -2.97K | -5.46M | -5.19M | -1.74M | -329.98M | 20.41M | 103.97M |
| Capital Expenditures | -1.3K | -5.46M | -5.19M | -1.85M | -34.2M | -29.51M | -15.2M |
| CapEx % of Revenue | - | - | - | - | - | 38827.63% | 1701.68% |
| Acquisitions | -1.66K | 0 | 1K | 108K | 0 | 0 | 18.21M |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 20K | 19.99M | 71.47M | 548.52M | -9.55M | 144.41M | 25.57M |
| Debt Issued (Net) | 0 | -11K | -30K | -32K | -52K | -54K | -26K |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | -1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -9.5M | 0 | 0 |
| Other Financing | 20K | 20M | 0 | 542.5M | 0 | 140K | 0 |
| Net Change in Cash | 15.23K▲ 0% | -10.65M▼ 70033.0% | 15.98M▲ 250.1% | 469.69M▲ 2839.3% | -429.6M▼ 191.5% | 38.47M▲ 109.0% | 9.42M▼ 75.5% |
| Free Cash Flow | -78.11K▲ 0% | -30.64M▼ 39122.4% | -55.49M▼ 81.1% | -78.94M▼ 42.2% | -124.27M▼ 57.4% | -155.86M▼ 25.4% | -120.12M▲ 22.9% |
| FCF Margin % | - | - | - | - | - | -205078.95% | -13450.95% |
| FCF Growth % | - | -39122.39% | -81.12% | -42.25% | -57.43% | -25.42% | 22.93% |
| FCF per Share | -0.00 | -0.16 | -1.74 | -1.28 | -2.01 | -1.59 | -0.90 |
| FCF Conversion (FCF/Net Income) | 0.00x | 0.94x | 0.91x | 0.71x | 2.54x | 2.07x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 145K | 68K | 1.95M | 2.86M | 73K | 0 |
PROK Key Ratios
ProKidney Corp. (PROK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -501.26% | -207.78% | -299.86% | -40.62% | -7.91% | -15.43% | -43.17% |
| Return on Invested Capital (ROIC) | -3365.46% | -470.58% | -568.61% | -926.23% | -64.53% | -42.99% | -49.41% |
| Gross Margin | - | - | - | - | - | 100% | -540.76% |
| Net Margin | - | - | - | - | - | -80507.89% | -16977.83% |
| Debt / Equity | 0.07x | 0.16x | 0.05x | 0.00x | 0.01x | 0.01x | 0.01x |
| Interest Coverage | - | - | - | -711.66x | -12626.83x | -20408.44x | -41251.75x |
| FCF Conversion | 0.00x | 0.94x | 0.91x | 0.71x | 2.54x | 2.07x | 0.79x |
| Revenue Growth | - | - | - | - | - | - | 1075% |
PROK SEC Filings & Documents
ProKidney Corp. (PROK) SEC filings — annual & quarterly reports (10-K, 10-Q)
PROK Frequently Asked Questions
ProKidney Corp. (PROK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ProKidney Corp. (PROK) reported $0.9M in revenue for fiscal year 2025.
ProKidney Corp. (PROK) grew revenue by 1075.0% over the past year. This is strong growth.
ProKidney Corp. (PROK) reported a net loss of $69.0M for fiscal year 2025.
Dividend & Returns
ProKidney Corp. (PROK) has a return on equity (ROE) of -43.2%. Negative ROE indicates the company is unprofitable.
ProKidney Corp. (PROK) had negative free cash flow of $129.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More PROK
ProKidney Corp. (PROK) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates